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NOT ALL PATIENTS ARE AVERAGE:THE IMPORTANCE OF
RECOGNISING PATIENT HETEROGENEITY
Van Staa TP1, Geusens P2, Boonen A2, Leufkens HG3, Cooper C4
1General Practice Research Database, London, UK, 2University
Hospital, Maastricht,The Netherlands, 3Utrecht University, Utrecht,
The Netherlands, 4University of Southampton, Southampton, UK
OBJECTIVES: Cost-effectiveness analyses are routinely based on
data from group averages, restricting its generalizibility to those
with below- or above-average risk. A pharmaco-economic model
was developed that used individualised risks, taking as example
bisphosphonates and prevention of fractures. METHODS: Data
were obtained from a research database of general practitioners,
comprising a sample of the UK general population of women
>50 years (N = 330,000). Individual mortality and hip, verte-
bral, and other osteoporotic fracture risks were estimated by age,
sex, body mass index, smoking and other clinical risk factors.
Estimates on costs, EQ5D utilities and treatment efﬁcacy were
obtained from a UK national report (NICE) and outcomes were
simulated over a ten-year period. RESULTS: There was a large
variability in the cost-effectiveness with clinical risk factors. At
age 60–69, the cost per QALY gained was ≤136k in women with
low fracture risk but ≤36k with high fracture risk (data for
women without fracture history). Patients with low body mass
index (<20) had considerable better cost-effectiveness than
patients with high BMI (≥26) (≤23k versus ≤71k at age 60–79
in women without fracture history). The same was found for 
different diseases such as rheumatoid arthritis or inﬂammatory
bowel disease. Using a cost-acceptability ratio of ≤30k per
QALY gained, bisphosphonates became cost-effective for
patients with a 5-year risk of 9.3% (95% CI 8.0–10.5%) for
osteoporotic fractures and of 2.1% (95% CI 1.5–2.7%) for hip
fractures. Including bone mineral density in the risk assessment,
the cost per QALY gained was ≤35k in women at age 60 with
a fracture history and a T-score of -2.5 (at age 80, this was 
≤3k). CONCLUSIONS: A pharmaco-economic model based on
individual long-term risks (as derived from a health care data-
base) can improve the targeting in a cost-effective manner of
therapy to patients.
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BAYESIAN ESTIMATION OF COST-EFFECTIVENESS ADJUSTED
FOR REAL WORLD CONSIDERING STATISTICAL ERRORS IN
CLINICAL TRIALS
Moriwaki K, Kamae I,Yanagisawa S,Araki D, Gandulam C
Kobe University, Kobe, Hyogo, Japan
Although evidence-based treatment is a norm for practice, the
efﬁcacy of treatment presented in clinical trials does not neces-
sarily guarantee its full size of beneﬁt in a real world. One of the
factors to be considered is statistical error, which may cause a
discrepancy between “efﬁcacy” in a clinical trial and “effective-
ness” in real practice. OBJECTIVES: The purpose of this study
is to formulate the inﬂuence on the cost-effectiveness in practice
caused by statistical errors when a treatment is undertaken on
the basis of the evidence proven in a clinical trial. METHODS:
A decision analysis was performed by decision-tree modeling
with treatment options that reﬂected the alternatives: take a new
treatment A (TA) vs. a conventional treatment B (TB), depend-
ing on the evidence resulted from a clinical trial. The rule for
selecting a treatment is: 1) take TA if the clinical trial conﬁrmed
better efﬁcacy with TA than TB, or 2)keep using TB if failed to
prove dominancy of TA over TB. Also the decision tree modeled
Bayesian prior probabilities at the chance node in the ﬁrst depth
with both the null hypothesis H0 and the alternative H1 (in efﬁ-
cacy, TA = TB, and TA > TB, respectively). RESULTS: Folding-
back and averaging-out procedures in the decision-tree led to 
a mathematical formula with the parameters such as cost-
effectiveness ratios, type I and type II errors, and Bayesian prior
probabilities for treatment effect. Numerical analysis for the
developed formula delineated an expected decrease of cost-
effectiveness is not always negligible depending on the statistical
power of the clinical trial and also on the degree of prior belief
in a new treatment from the standpoint of Bayes. CONCLU-
SIONS: In case of need for adjusting cost-effectiveness from clin-
ical trial into real practice, the formula newly developed can be
a tool to measure the degree of the adjustment.
METHODS & CONCEPTS—Patient Reported Outcomes
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MEASURING SOCIAL PREFERENCES FOR EQ-5D HEALTH
STATES: NEW SOLUTIONS TO OLD PROBLEMS
Kind P, Macran S
University of York,York, UK
OBJECTIVES: The standard version of EQ-5D deﬁnes 243
health states. Eliciting corresponding social preference weights is
a labour/resource intensive exercise—witness the scale of the
original 1993 UK valuation study and the subsequent US repli-
cation study. This stems from the requirement to use TTO
methods in face-face interviews. Furthermore, given the need to
minimise respondent burden only a subset of 45 health states are
directly valued. These data are used to construct an estimation
model used to interpolate values for the remaining health states.
The complexity of this modelling represents a daunting chal-
lenge. Simpler methods are called for. This paper reports on a
study in which values for all EQ-5D health states were obtained
directly. METHODS: The EuroQoL Group has a standard ques-
tionnaire for use in collecting valuations in postal surveys. 
Multiple versions of this questionnaire were designed, each pre-
senting a subset of 16 EQ-5D health states drawn from across
the severity range. Values for health states are assessed on a
0–100 scale that represents worst-best imaginable health. A total
of 1100 questionnaires were mailed to a sample of respondents
selected from the electoral registers of England and Wales. Data
from 685 respondents were subsequently analysed. RESULTS:
OLS regression was used to determine the value decrements asso-
ciated with increased problems on each EQ-5D dimension.The
adjusted R2 for this model is 0.907. Mean values from this survey
were compared with mean VAS scores elicited in the original
1993 survey. For 30/45 health states values were remarkably
similar and differed by less than 5 points. The highest propor-
tional difference occurs for dead with a value in 2003 that is
45% higher than that recorded in 1993. CONCLUSIONS: The
direct valuation of EQ-5D health states is feasible and yields
robust results that avoid the use of problematic TTO procedures.
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CONVERTING SF-36 INTO EQ-5D: DESIGNED TO SUCCEED OR
CALCULATED TO FAIL?
Chuang LH, Kind P
University of York,York, UK
BACKGROUND: In its original format SF-36 is a proﬁle
measure that results in 2 or more subscale scores. This design
means that SF-36 cannot be used in cost-effectiveness analysis in
which health outcomes must be represented as a single summary
index of the type exempliﬁed by EQ-5Dindex. However, many clin-
ical studies continue to report outcomes in terms of SF-36 and
the researchers continue to confront the challenge of “salvaging”
such data for use in economic analysis. This paper reviews the
dangers in using SF-36/EQ-5D conversion models that have been
